This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

JAMA. 2002;288:2533-2535.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

MMWR. 2002;51:989-993

1 figure, 1 table omitted

In June 2001, seven cases of yellow fever vaccine–associated viscerotropic disease (YEL-AVD) (previously called multiple organ system failure) in recipients of 17D-derived yellow fever vaccine (YEL) were reported to the Advisory Committee on Immunization Practices (ACIP).^1-3 ACIP reviewed the cases, recommended enhanced surveillance for adverse events, and updated the ACIP statement on YEL.⁴ This report summarizes the preliminary surveillance findings, including two new suspected cases of YEL-AVD and four suspected cases of YEL-associated neurotropic disease (YEL-AND) (previously called postvaccinal encephalitis). Although YEL remains essential for travelers to areas in which yellow fever (YF) is endemic, these findings underscore the need for continued enhanced surveillance and timely clinical assessment of YEL-associated disease.

The Vaccine Adverse Event Reporting System (VAERS) receives reports of adverse events following licensed vaccine administration in the United States.⁵ Enhanced surveillance for YEL adverse events was initiated in June 2001 and . . . [Full Text of this Article]

Case 1

Case 2

Case 3

Case 4

Case 5

Case 6

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?